Gosset Ownership
Private
Employees
~300
Therapeutic Areas
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
MAXVAX Biotechnology General Information
MAXVAX has successfully enrolled subjects in Phase II clinical trials for its RSV vaccine and is advancing other vaccine candidates through clinical stages.
Contact Information
Primary Industry
Biotech
Corporate Office
Chengdu, Sichuan
China
China
Drug Pipeline
RSV vaccine
Phase 2Key Partnerships
Shenzhen Capital Group, Gates Foundation
MAXVAX Biotechnology Funding
No funding data available
To view MAXVAX Biotechnology's complete valuation and funding history, request access »